422149 reflects a bearish or protective position which profits with stock below $21.35 at expiration. Secondaries (announced/priced): N/A IPO's: Cancer Genetics (CGIX) files $50M through MBlair & Baird Key Research: Barcap upgrades RPXC/CYMI/LSI/MU & downgrades AMAT/CODE/FSL/INTC/MCHP & initiates CXS (ew) a

on of the protein 1790M within the EGFR kinasc domain. PED's work caught the attention of Dr. Ben Vogelstein. the Director of the Ludwig Ccntcr for Cancer Genetics and Therapeutics at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University School of Medicine. Dr. Vogelstein was studying resist